Full text is available at the source.
JAMA··
Oral Semaglutide compared to Placebo and Injectable Semaglutide for Blood Sugar Control in Type 2 Diabetes
Updated
Abstract
Mean change in hemoglobin A1c level decreased by 0.4% to 1.6% with oral semaglutide compared to placebo.
- Oral semaglutide showed a dosage-dependent reduction in HbA1c levels, ranging from -0.7% to -1.9%.
- Subcutaneous semaglutide led to a decrease in HbA1c of -1.9%, while placebo resulted in a change of -0.3%.
- Body weight reductions with oral semaglutide ranged from -2.1 kg to -6.9 kg, significantly greater than the -1.2 kg change with placebo.
- Significant weight loss was observed with oral semaglutide dosages of 10 mg or more compared to placebo.
- Adverse events were reported by 63% to 86% of patients in the oral semaglutide groups, with gastrointestinal issues being the most common.
Simplified
IMPORTANCE: Glucagon-like peptide-1 (GLP-1) receptor agonists are effective therapies for the treatment of type 2 diabetes and are all currently available as an injection.
OBJECTIVES: To compare the effects of oral semaglutide with placebo (primary) and open-label subcutaneous semaglutide (secondary) on glycemic control in patients with type 2 diabetes.
DESIGN, SETTING, AND PATIENTS: Phase 2, randomized, parallel-group, dosage-finding, 26-week trial with 5-week follow-up at 100 sites (hospital clinics, general practices, and clinical research centers) in 14 countries conducted between December 2013 and December 2014. Of 1106 participants assessed, 632 with type 2 diabetes and insufficient glycemic control using diet and exercise alone or a stable dose of metformin were randomized. Randomization was stratified by metformin use.
INTERVENTIONS: Once-daily oral semaglutide of 2.5 mg (n = 70), 5 mg (n = 70), 10 mg (n = 70), 20 mg (n = 70), 40-mg 4-week dose escalation (standard escalation; n = 71), 40-mg 8-week dose escalation (slow escalation; n = 70), 40-mg 2-week dose escalation (fast escalation, n = 70), oral placebo (n = 71; double-blind) or once-weekly subcutaneous semaglutide of 1.0 mg (n = 70) for 26 weeks.
MAIN OUTCOMES AND MEASURES: The primary end point was change in hemoglobin A1c (HbA1c) from baseline to week 26. Secondary end points included change from baseline in body weight and adverse events.
RESULTS: Baseline characteristics were comparable across treatment groups. Of the 632 randomized patients (mean age, 57.1 years [SD, 10.6]; men, 395 (62.7%); diabetes duration, 6.3 years [SD, 5.2]; body weight, 92.3 kg [SD, 16.8]; BMI, 31.7 [SD, 4.3]), 583 (92%) completed the trial. Mean change in HbA1c level from baseline to week 26 decreased with oral semaglutide (dosage-dependent range, -0.7% to -1.9%) and subcutaneous semaglutide (-1.9%) and placebo (-0.3%); oral semaglutide reductions were significant vs placebo (dosage-dependent estimated treatment difference [ETD] range for oral semaglutide vs placebo, -0.4% to -1.6%; P = .01 for 2.5 mg, <.001 for all other dosages). Reductions in body weight were greater with oral semaglutide (dosage-dependent range, -2.1 kg to -6.9 kg) and subcutaneous semaglutide (-6.4 kg) vs placebo (-1.2 kg), and significant for oral semaglutide dosages of 10 mg or more vs placebo (dosage-dependent ETD range, -0.9 to -5.7 kg; P < .001). Adverse events were reported by 63% to 86% (371 of 490 patients) in the oral semaglutide groups, 81% (56 of 69 patients) in the subcutaneous semaglutide group, and 68% (48 of 71 patients) in the placebo group; mild to moderate gastrointestinal events were most common.
CONCLUSIONS AND RELEVANCE: Among patients with type 2 diabetes, oral semaglutide resulted in better glycemic control than placebo over 26 weeks. These findings support phase 3 studies to assess longer-term and clinical outcomes, as well as safety.
TRIAL REGISTRATION: clinicaltrials.gov Identifier: NCT01923181.
Related papers
Sep '15
Finding the Right Dose of Once-Weekly Semaglutide Compared to Placebo and Daily Liraglutide in People with Type 2 Diabetes
top 1% journal
cited by 165 papers
randomized controlled trial
Mar '19
Additional Oral Semaglutide vs Sitagliptin and Their Effects on Blood Sugar Control in Adults with Type 2 Diabetes Not Controlled by Metformin Alone or with Sulfonylurea
cited by 357 papers
randomized controlled trial
Jul '24
Effectiveness and safety of oral semaglutide alone compared to placebo in mostly Chinese adults with type 2 diabetes
top 2% journal
cited by 24 papers
randomized controlled trial
Jun '19
Comparing oral semaglutide, injected liraglutide, and placebo in type 2 diabetes treatment
top 1% journal
cited by 472 papers
randomized controlled trial
Jan '22
Weekly Semaglutide Compared to Daily Liraglutide for Weight Loss in Adults with Overweight or Obesity Without Diabetes
top 1% journal
cited by 821 papers
randomized controlled trial
Apr '17
Weekly semaglutide compared to daily sitagliptin added to diabetes pills in type 2 diabetes over 56 weeks: a safety and effectiveness trial
top 1% journal
cited by 420 papers
randomized controlled trial
Jul '24
Effectiveness and safety of oral semaglutide compared to sitagliptin in mostly Chinese adults with type 2 diabetes not controlled by metformin
top 2% journal
cited by 19 papers
randomized controlled trial
Feb '22
Tirzepatide injection added to adjusted insulin improves blood sugar control in type 2 diabetes compared to placebo
top 1% journal
cited by 528 papers
randomized controlled trial
Jun '21
Comparing Weekly Tirzepatide and Semaglutide in People with Type 2 Diabetes
🏆 top 0.1% journal
cited by 1,722 papers
randomized controlled trial
Mar '17
Effectiveness and safety of weekly semaglutide compared to daily insulin glargine added to metformin in people with type 2 diabetes who have not used insulin
top 1% journal
cited by 393 papers
randomized controlled trial